These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11169171)

  • 21. 8-Methoxypsoralen serum levels in poor responders to photochemotherapy. Importance of drug formulation and individual factors.
    Walther T; Haustein UF
    Int J Dermatol; 1991 Jul; 30(7):516-8. PubMed ID: 1769779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of food on 8-methoxypsoralen serum concentration and minimal phototoxic dose.
    Bech-Thomsen N; Angelo HR; Knudsen EA
    Br J Dermatol; 1992 Dec; 127(6):620-4. PubMed ID: 1476921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA.
    Hannuksela-Svahn A; Pukkala E; Koulu L; Jansén CT; Karvonen J
    J Am Acad Dermatol; 1999 May; 40(5 Pt 1):694-6. PubMed ID: 10321595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phototesting in bath-PUVA: marked reduction of 8-methoxypsoralen (8-MOP) activity within one hour after an 8-MOP bath.
    Schempp CM; Schöpf E; Simon JC
    Photodermatol Photoimmunol Photomed; 1996 Jun; 12(3):100-2. PubMed ID: 8956358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatment.
    Sakuntabhai A; Diffey BL; Farr PM
    Br J Dermatol; 1995 Dec; 133(6):919-23. PubMed ID: 8547045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
    Treffel P; Makki S; Humbert P; Khaldoun H; Agache P
    Acta Derm Venereol; 1992; 72(1):65-7. PubMed ID: 1350152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bath PUVA--an investigation of the distribution of trioxsalen (TMP) and 8-methoxypsoralen (8-MOP) in bathwater.
    Wainwright NJ; MacLeod TM; Ferguson J
    Photodermatol Photoimmunol Photomed; 1997; 13(1-2):17-20. PubMed ID: 9361123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans.
    Billard V; Gambus PL; Barr J; Minto CF; Corash L; Tessman JW; Stickney JL; Shafer SL
    Br J Clin Pharmacol; 1995 Oct; 40(4):347-60. PubMed ID: 8554937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 8-MOP aqueous bath and 8-MOP ethanolic lotion (Meladinine) in local PUVA therapy.
    Shephard SE; Schregenberger N; Dummer R; Panizzon RG
    Dermatology; 1998; 197(1):25-30. PubMed ID: 9693181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Permeation characteristics of 8-methoxypsoralen through human skin; relevance to clinical treatment.
    Anigbogu AN; Williams AC; Barry BW
    J Pharm Pharmacol; 1996 Apr; 48(4):357-66. PubMed ID: 8794983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrofluorimetric determination of 5-methoxypsoralen pharmacokinetic in patients' serum.
    Saïd A; Makki S; Muret P; Toubin G; Humbert P; Millet J
    Exp Dermatol; 1997 Apr; 6(2):57-63. PubMed ID: 9209885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis.
    Calzavara-Pinton P; Ortel B; Carlino A; Honigsmann H; De Panfilis G
    Exp Dermatol; 1992 Jul; 1(1):46-51. PubMed ID: 1344660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy.
    Shephard SE; Panizzon RG
    Dermatology; 1999; 199(2):106-12. PubMed ID: 10559574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in 8-methoxypsoralen profiles during long-term psoralen plus ultraviolet A therapy and correlations between serum 8-methoxypsoralen levels and chromametric parameters.
    Marrakchi S; Decloquement L; Pollet P; Briand G; Loesche C; Bocquet JL; Degand P; Thomas P
    Photodermatol Photoimmunol Photomed; 1991 Oct; 8(5):206-11. PubMed ID: 1822684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
    Calzavara-Pinton PG; Zane C; Carlino A; De Panfilis G
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis.
    Collins P; Rogers S
    Br J Dermatol; 1992 Oct; 127(4):392-5. PubMed ID: 1419760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
    Hönigsmann H; Jaschke E; Gschnait F; Brenner W; Fritsch P; Wolff K
    Br J Dermatol; 1979 Oct; 101(4):369-78. PubMed ID: 508604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
    George SA; Ferguson J
    Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):33-5. PubMed ID: 1390121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients.
    Herfst MJ; De Wolff FA
    Clin Pharmacol Ther; 1983 Jul; 34(1):117-24. PubMed ID: 6861433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma levels of 8-methoxypsoralen following oral or bath-water treatment.
    Thomas SE; O'Sullivan J; Balac N
    Br J Dermatol; 1991 Jul; 125(1):56-8. PubMed ID: 1873204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.